Kronos Bio has been granted a patent for inhibitors of CDK9, specifically pyrazolo[1,5-a]pyrimidine derivatives and salts thereof. The patent claims a method for modulating cyclin-dependent kinase 9/cyclin T1 activity in a patient by administering a compound of a specific formula. GlobalData’s report on Kronos Bio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kronos Bio, Cancer treatment biomarkers was a key innovation area identified from patents. Kronos Bio's grant share as of January 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11845754B2) discloses a method for modulating cyclin-dependent kinase 9/cyclin T1 activity in patients by administering a compound of a specific formula. The method aims to treat patients with cyclin-dependent kinase 9 mediated diseases, including various types of leukemia, breast cancer, liver cancer, lymphoma, lung cancer, and multiple myeloma.
Furthermore, the patent claims cover the treatment of cyclin-dependent kinase 9 mediated diseases caused by aberrant expression of specific proteins such as MCL-1 and MYC, encompassing both hematologic malignancies and solid tumors. The method involves administering a pharmaceutical composition containing the compound along with a pharmaceutically acceptable carrier to achieve modulation of cyclin-dependent kinase 9/cyclin T1 activity in patients with these specific disease conditions. This patent provides a novel approach to targeting these diseases at a molecular level, potentially offering new treatment options for patients in need.
To know more about GlobalData’s detailed insights on Kronos Bio, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
